Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Leading cardiac assist devices maker, Abiomed Inc. (ABMD - Analyst Report), provided encouraging preliminary data for its fourth-quarter 2013 results. The company will report full results on May 2, 2013.

Revenues climbed 17% year over year to $43.7 million. It increased 14% sequentially, reflecting solid Impella product sales. For fiscal 2013, revenues grew 25% to $158.1 million, which was above the company’s guidance of $155–$157 million.

The current Zacks Consensus Estimates for revenues for the fourth quarter and fiscal 2013 are $42 million and $156 million, respectively.

Preliminary global Impella sales for the fourth quarter increased 22% to $39.3 million, while the same for fiscal 2013 grew 31% to $106.9 million. It also surpassed the company’s expectation of achieving 30% year over year growth.

Further, preliminary U.S. Impella sales grew 22% to $36.5 million. Abiomed opened 30 new U.S. Impella 2.5 sites in the quarter to end with 748 customer sites. Additionally, Impella CP was sold to 55 hospitals, bringing the total to 101 customer sites. For fiscal 2013, U.S. Impella revenues increased 32% to $131.3 million.

Our Take

Mass.-based Abiomed is engaged in developing, manufacturing and marketing of medical products designed to assist or replace the pumping function of the failing heart. It is enjoying a strong demand for its Impella products. Impella utilization continues to grow at a healthy pace, as is evident from the increasing number of patients being treated with the device.

The current Zacks Consensus Estimates for earnings for the fourth quarter and fiscal 2013 are 7 cents and 34 cents, respectively.

The company has a Zacks Rank #2 (Buy). Other medical stocks such as Cepheid (CPHD - Analyst Report), Cyberonics (CYBX - Analyst Report) and NuVasive (NUVA - Snapshot Report) with a Zacks Rank #1 (Strong Buy) appear impressive.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%